Isodiol International Inc. (ISOLF) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Isodiol International Inc. (ISOLF), Healthcare sektöründe faaliyet gösteriyor, son olarak $'dan işlem görüyor ve 0 piyasa değerine sahip. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 43/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 16 Mar 2026Isodiol International Inc. (ISOLF) Sağlık ve Boru Hattı Genel Bakışı
Isodiol International Inc. operates in the hemp-based consumer packaged goods sector, focusing on developing and marketing phytoceutical products in Canada and the United States. The company utilizes pharmaceutical-grade cannabinoid crystalline isolates and advanced technologies like micro-encapsulation, serving both consumable and topical skincare markets, but faces challenges common to OTC-listed companies.
Yatırım Tezi
Investing in Isodiol International Inc. presents a high-risk, high-reward scenario. The company operates in the rapidly evolving hemp-based consumer packaged goods market, which offers significant growth potential. However, Isodiol's negative profit margin of -542.1% and gross margin of -24.3% indicate substantial financial challenges. The company's success hinges on its ability to achieve profitability through scaling its operations, optimizing its cost structure, and successfully launching new products. Key catalysts include expanding distribution networks and securing regulatory approvals for its pharmaceutical products. The OTC listing adds further complexity, requiring careful due diligence to assess liquidity and transparency.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market Cap of $0.00B indicates a micro-cap company with potential for high volatility.
- Negative P/E ratio of -0.00 reflects the company's current lack of profitability.
- Profit Margin of -542.1% signals significant operational inefficiencies and challenges in achieving profitability.
- Gross Margin of -24.3% demonstrates that the cost of goods sold exceeds revenue, highlighting the need for cost reduction strategies.
- Beta of -0.20 suggests the stock is less volatile than the market, but this may also reflect low trading volume and limited investor interest.
Rakipler & Benzerleri
Güçlü Yönler
- Innovative product formulations and delivery methods.
- Focus on pharmaceutical-grade cannabinoid isolates.
- Established distribution networks in key markets.
- Diverse product portfolio across consumer and pharmaceutical segments.
Zayıflıklar
- Negative profit and gross margins.
- Limited financial resources.
- Dependence on regulatory approvals.
- OTC listing and associated risks.
Katalizörler
- Upcoming: Potential regulatory approvals for pharmaceutical products in key markets.
- Ongoing: Expansion of distribution networks across Canada and the United States.
- Ongoing: Development and launch of new hemp-based product formulations.
- Upcoming: Strategic partnerships and acquisitions to expand market reach.
- Ongoing: Increasing consumer acceptance of CBD and other hemp-derived products.
Riskler
- Potential: Intense competition in the hemp-based products market.
- Ongoing: Changing regulatory landscape and potential for stricter regulations.
- Potential: Fluctuations in raw material prices and supply chain disruptions.
- Potential: Negative publicity or consumer perception issues related to hemp-based products.
- Ongoing: Limited financial resources and negative profit margins.
Büyüme Fırsatları
- Expansion of Distribution Networks: Isodiol can grow by expanding its distribution networks across Canada and the United States. The market for hemp-based products is growing, with projections estimating the U.S. CBD market to reach billions of dollars in the coming years. Establishing partnerships with major retailers and distributors can significantly increase product visibility and accessibility, driving sales growth. Timeline: Ongoing, with continuous efforts to secure new distribution agreements.
- New Product Development and Innovation: Isodiol can capitalize on the growing demand for innovative hemp-based products by investing in research and development. Developing new formulations, delivery methods, and product categories can attract new customers and increase market share. Focus on unique and differentiated products, such as pharmaceutical-grade cannabinoid isolates, can provide a competitive edge. Timeline: Ongoing, with continuous product development cycles.
- Strategic Partnerships and Acquisitions: Isodiol can pursue strategic partnerships and acquisitions to expand its product portfolio, market reach, and technological capabilities. Collaborating with complementary businesses can create synergies and accelerate growth. Acquiring smaller companies with innovative technologies or established distribution networks can provide a competitive advantage. Timeline: Opportunistic, based on market conditions and available opportunities.
- Regulatory Approvals for Pharmaceutical Products: Securing regulatory approvals for its pharmaceutical products can unlock significant growth opportunities for Isodiol. Obtaining FDA or other regulatory approvals can validate the safety and efficacy of its products, increasing consumer confidence and market acceptance. This can also open up new markets and distribution channels, such as pharmacies and healthcare providers. Timeline: Dependent on regulatory timelines and clinical trial results.
- International Expansion: Isodiol can explore opportunities to expand its operations into international markets. The global market for hemp-based products is growing rapidly, with significant potential in Europe, Asia, and Latin America. Adapting its product portfolio and marketing strategies to local market conditions can drive international sales growth. Timeline: Long-term, with careful consideration of regulatory and market conditions.
Fırsatlar
- Expansion into new geographic markets.
- Development of new hemp-based products and applications.
- Strategic partnerships and acquisitions.
- Increasing consumer acceptance of CBD and other hemp-derived products.
Tehditler
- Intense competition in the hemp-based products market.
- Changing regulatory landscape.
- Fluctuations in raw material prices.
- Potential negative publicity or consumer perception issues.
Rekabet Avantajları
- Proprietary formulations and manufacturing processes.
- Focus on pharmaceutical-grade cannabinoid isolates.
- Advanced delivery technologies like micro-encapsulation.
- Established distribution networks in Canada and the United States.
ISOLF Hakkında
Isodiol International Inc., headquartered in Vancouver, Canada, is engaged in the development, marketing, distribution, and sale of hemp-based consumer packaged goods and solutions within Canada and the United States. The company formulates and manufactures phytoceutical consumer products, leveraging pharmaceutical and nutraceutical grade phytochemical compounds. Isodiol's product portfolio includes pharmaceutical-grade cannabinoid crystalline isolates derived from hemp, micro-encapsulations, and nanotechnology applications for consumable and topical skin care products. These technologies are used to enhance the delivery and efficacy of their products. Isodiol also manufactures and distributes hemp oil and nicotine e-liquids, catering to the evolving preferences of consumers in the wellness and lifestyle sectors. The company further extends its reach through personal care products, apparel, merchandising solutions, and hemp-infused beverages. Additionally, Isodiol supplies pharmaceutical products, aiming to serve a broad spectrum of consumer and business needs within the hemp and cannabinoid markets. The company's focus on innovation and diverse product offerings positions it to capitalize on the growing demand for hemp-derived products, while navigating the regulatory complexities of the industry.
Ne Yaparlar
- Develops and markets hemp-based consumer packaged goods.
- Manufactures phytoceutical consumer products.
- Offers pharmaceutical-grade cannabinoid crystalline isolates.
- Utilizes micro-encapsulation and nanotechnology for product delivery.
- Distributes hemp oil and nicotine e-liquids.
- Provides apparel and merchandising solutions.
- Manufactures and sells hemp-infused beverages.
- Supplies pharmaceutical products.
İş Modeli
- Develops and manufactures hemp-based products.
- Markets and distributes products through various channels.
- Generates revenue through product sales.
- Focuses on both consumer and pharmaceutical markets.
Sektör Bağlamı
Isodiol International Inc. operates within the burgeoning hemp-based consumer packaged goods industry, which has experienced rapid growth due to increasing consumer acceptance of CBD and other hemp-derived products. The market is characterized by intense competition, with numerous companies vying for market share. Key trends include the development of innovative product formulations, expansion of distribution channels, and increasing regulatory scrutiny. Isodiol's focus on pharmaceutical-grade cannabinoid isolates and advanced delivery technologies positions it to potentially capture a niche within this competitive landscape, provided it can overcome its financial challenges.
Kilit Müşteriler
- Consumers seeking hemp-based wellness products.
- Retailers and distributors of consumer packaged goods.
- Pharmaceutical companies and healthcare providers.
- Individuals interested in hemp oil and nicotine e-liquids.
Finansallar
Grafik & Bilgi
Isodiol International Inc. (ISOLF) hisse senedi fiyatı: Price data unavailable
Son Haberler
-
Washington Post Reported President Trump Expected To Announce A Medicare Pilot Program To Reimburse Patients' CBD Treatments
benzinga · 18 Ara 2025
-
'Trump to sign executive order reclassifying marijuana: Officials' -ABC Report
benzinga · 17 Ara 2025
-
Hess Midstream Signs $100M Repurchase That Includes Class B Units Of Hess Midstream Operations From chevron Affiliate And Hess Midstream's Class A Shares From Public
benzinga · 5 Ağu 2025
-
'GOP-Led Congressional Panel Demands Investigation On Biden's Marijuana Rescheduling Process, Citing 'Deviations' And 'Mental Health Hazards'' -Marijuana Moment Report
benzinga · 10 Haz 2025
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
ISOLF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
ISOLF için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, ISOLF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Son Haberler
Washington Post Reported President Trump Expected To Announce A Medicare Pilot Program To Reimburse Patients' CBD Treatments
'Trump to sign executive order reclassifying marijuana: Officials' -ABC Report
Hess Midstream Signs $100M Repurchase That Includes Class B Units Of Hess Midstream Operations From chevron Affiliate And Hess Midstream's Class A Shares From Public
'GOP-Led Congressional Panel Demands Investigation On Biden's Marijuana Rescheduling Process, Citing 'Deviations' And 'Mental Health Hazards'' -Marijuana Moment Report
Yönetim: Marcos Agramont
CEO
Marcos Agramont serves as the CEO of Isodiol International Inc. His background includes experience in the consumer packaged goods and pharmaceutical industries. He has held various leadership positions, focusing on strategic planning, business development, and operational management. His expertise spans across product development, marketing, and distribution, with a focus on driving growth and innovation. Agramont's experience is geared towards navigating the complexities of the hemp-based products market.
Sicil: Under Marcos Agramont's leadership, Isodiol International Inc. has focused on expanding its product portfolio and distribution networks. Key milestones include the development of new hemp-based formulations and the establishment of strategic partnerships. The company has also navigated regulatory challenges and adapted to the evolving market landscape. His focus has been on positioning Isodiol as a leader in the hemp-based consumer packaged goods sector.
ISOLF OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, indicating that Isodiol International Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial reporting, increasing the risk for investors. Unlike NYSE or NASDAQ-listed companies, OTC Other firms face fewer regulatory requirements, leading to greater information asymmetry and potential for fraud or manipulation. Investors should exercise extreme caution and conduct thorough due diligence before investing in OTC Other stocks.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation and volatility.
- Higher risk of fraud or mismanagement.
- Uncertain regulatory environment for hemp-based products.
- Verify the company's financial statements and disclosures.
- Assess the company's management team and their track record.
- Research the company's business model and competitive landscape.
- Evaluate the company's regulatory compliance and risk management practices.
- Monitor trading volume and price volatility.
- Consult with a qualified financial advisor.
- Understand the risks associated with OTC investing.
- Established presence in the hemp-based products market.
- Focus on pharmaceutical-grade cannabinoid isolates.
- Partnerships with reputable retailers and distributors.
- Commitment to regulatory compliance.
- Development of innovative product formulations and delivery methods.
Isodiol International Inc. Hissesi: Cevaplanan Temel Sorular
ISOLF için değerlendirilmesi gereken temel faktörler nelerdir?
Isodiol International Inc. (ISOLF) şu anda yapay zeka skoru 43/100, düşük puanı gösteriyor. Temel güçlü yan: Innovative product formulations and delivery methods.. İzlenmesi gereken birincil risk: Potential: Intense competition in the hemp-based products market.. Bu bir finansal tavsiye değildir.
ISOLF MoonshotScore'u nedir?
ISOLF şu anda MoonshotScore'da 43/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
ISOLF verileri ne sıklıkla güncellenir?
ISOLF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler ISOLF hakkında ne diyor?
ISOLF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
ISOLF'a yatırım yapmanın riskleri nelerdir?
ISOLF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Intense competition in the hemp-based products market.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
ISOLF'ın P/E oranı nedir?
ISOLF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için ISOLF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
ISOLF aşırı değerli mi, yoksa düşük değerli mi?
Isodiol International Inc. (ISOLF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
ISOLF'ın temettü verimi nedir?
Isodiol International Inc. (ISOLF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Limited financial data available for comprehensive analysis.
- OTC listing introduces higher risk and uncertainty.
- Analyst coverage is limited due to the company's size and listing status.